Learning Objectives:

  1. Differentiate between the two most common forms of cardiac amyloidosis.
  2. Describe the current therapeutic landscape for AL amyloidosis.
  3. Describe the current and likely future therapeutic landscape for ATTR amyloidosis.


Session date: 
06/24/2022 - 12:00pm to 1:00pm CDT
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Ronald Witteles, MD